Educational protocol hub
PT-141 (Bremelanotide): protocol variants and reconstitution resources
Educational hub for PT-141 (Bremelanotide), grouping 2 available protocol variants with links to the exact dosage and reconstitution pages.
What this hub covers
This page groups the available PT-141 (Bremelanotide) protocol variants so readers can choose the exact vial-size guide without mixing formats.
Reconstitution workflow
Use the linked protocol pages and calculator resources to review concentration, diluent logic and unit conversions for the selected variant.
Research-only context
All information is educational and literature-focused. AllPeptides.eu does not sell peptides and does not provide medical advice.
Available protocol variants
Choose the exact guide you want to view.
PT-141 (Bremelanotide)
PT-141 (Bremelanotide) is a melanocortin receptor agonist, MC4R, FDA-approved (Vyleesi®, 2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women. 5mg vial — reconstitute with 1mL of bacteriostatic water for a concentration of 5mg/mL (500mcg per 10 units on a U-100 syringe).
View protocolPT-141 (Bremelanotide)
PT-141 (Bremelanotide) is an FDA-approved MC4R agonist (Vyleesi) for the treatment of hypoactive sexual desire disorder. Reconstitute with 2mL of bacteriostatic water for a concentration of 5mg/mL (500mcg per 10 units).
View protocolRelated research resources
Internal links that help readers and search engines understand this peptide topic cluster.
References
- Kingsberg SA et al. Obstet Gynecol 2019 — Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
View Source - MC4R Mechanism — Molinoff PB et al. PT-141: a melanocortin agonist for sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
View Source - Diamond LE et al. J Sex Med 2006 — An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
View Source - Clayton AH et al. J Womens Health (Larchmt) 2022 — Safety Profile of Bremelanotide Across the Clinical Development Program.
View Source
Educational and laboratory research information only. AllPeptides.eu does not sell peptides and does not provide medical advice or human-use instructions.